Daniel Grizelj The ADRs of Immutep Limited ( NASDAQ: IMMP ) fell on Wednesday after the Australian biotech announced the conclusion of a stock offering targeted at institutional investors. The Sydney-based cancer drug developer said the offer, comprising an institutional placement component (placement) and an institutional entitlement component (institutional entitlement offer), closed on June 4 with strong support from investors. Nearly 100% of eligible institutional investors took part in the offer, under which they will receive new fully paid ordinary shares of Immutep ( IMMP ).
The transactions, conducted under 1 for 16 pro rata bases, have generated approximately A$89.6M in gross proceeds for the company. Concurrently, Immutep ( IMMP ) announced an ~A$10.
6M retail entitlement offer, expected to run from June 7 to June 20. More on Immutep Immutep: Realizing The Expected Catalysts, With More To Come Immutep reports promising efti/Keytruda data for head and neck cancer Seeking Alpha’s Quant Rating on Immutep Historical earnings data for Immutep Financial information for Immutep.
